TLDRocket
Sign in

Isomorphic Labs

Company isomorphiclabs.com Covered in 5 stories + Follow ✴ AI Graph

Isomorphic Labs is Google's AI drug discovery subsidiary focused on using AI to identify novel drug targets and design therapeutics. The company raised $2.1 billion in a Series B funding round in H1 2026 and has developed the Isomorphic Drug Design Engine, which predicts drug-protein interactions and identifies previously unknown binding pockets on disease-associated proteins. Recently, Isomorphic Labs partnered with Google DeepMind on a bioresilience program to establish safeguards around AI use in biological contexts while making tools like AlphaFold available to government and biosecurity partners.

Updated 6 August 2026

Signals

0 stories (-100%)

Media momentum

As of 17 Sep 2026 · Visible stories in the last 30 days, compared with the 30 days before.

5 sources

Source diversity

As of 17 Sep 2026 · Distinct publications behind this entity's visible coverage.

Release activity

As of 17 Sep 2026 · Model, product and open-source release events in the last 90 days whose coverage involves this entity.

1 event

Funding signals

As of 17 Sep 2026 · Funding and acquisition events in the last 90 days whose coverage involves this entity.

Jun 2026 → Aug 2026

Coverage span

As of 17 Sep 2026 · First to most recent month of TLDRocket coverage of this entity.

Funding history

Latest developments

Timeline

Month Quarter Year

2026

Google announced a restructuring of its AI leadership, with Demis Hassabis stepping back from day-to-day DeepMind leadership and Jeff Dean and other senior researchers leaving to launch Discovery Loop Executive move

European tech funding reaches €30 billion in H1 2026 with increasing deal sizes and capital concentration Funding

Relationships

Products & technology

Partnerships

Investment & ownership

The daily briefing

Every AI story that matters, in your inbox by 8am.

TLDRocket reads all relevant sources, removes duplicate coverage, and summarises the day in two minutes. Follow companies and topics for alerts, or get the briefing in Slack. Free, no spam, unsubscribe anytime.